Eli Lilly and Company is a leading innovation-driven pharmaceutical corporation. We are developing a growing portfolio of best-in-class - often first-in-class - pharmaceutical products by applying the latest research from our own worldwide laboratories, by collaborating with eminent scientific organizations, by making use of the most up-to-date technological tools and by providing exceptional service to our customers. Through these internal programs and external initiatives, we're seeking answers for some of the world's most urgent medical needs.

Lilly products treat depression, schizophrenia, diabetes, cancer, osteoporosis and many other diseases. As our products save and improve lives, they also save overall health care costs. We employ more than 41,000 people worldwide, with more than 7,600 in research and development, and market our medicines in 158 countries. Lilly has major research and development facilities in nine countries and conducts clinical trials in more than 60 countries.

Lilly is 126 years old and is headquartered in Indianapolis, Ind., USA.

Lilly-NUS Centre for Clinical Pharmacology
Lilly-NUS Centre for Clinical Pharmacology Pte Ltd is the only Lilly Clinical Pharmacological unit outside U.S. with its own clinical research unit for conducting clinical trials with new pharmaceutical agents, and particularly exploring interethnic issues in man.

Lilly Singapore Centre for Drug Discovery
The Lilly Singapore Centre for Drug Discovery focuses on drug discovery research in the areas of cancer and metabolic disorders. The Centre also conducts biomarker discovery in these areas, and scientific computational research and development.